Ranbaxy Laboratories Ltd (RANB.BO)
|Market Cap (Mil.):||Rs245,440.09|
|Shares Outstanding (Mil.):||424.01|
MUMBAI - Generic drugmaker Ranbaxy Laboratories Ltd posted a net loss for the quarter to end-June after making a provision related to "ongoing settlement discussions" with U.S. government authorities.
* Loss of 1.86 bln rupees due to one-off 2.4 bln provision
MUMBAI, July 29 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by local rival Sun Pharmaceutical Industries Ltd, posted a net loss in the June quarter hit by a one-time provision.
ZURICH - Swiss drugmaker Novartis posted a quarterly rise in sales that missed expectations and said it would focus on eking out gradual cost savings to boost margins as it prepares a radical business overhaul.
MUMBAI - India has capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV, a move likely to hit the profit margins of drug firms such as Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.
* Move aimed towards making drugs more affordable in India
MUMBAI, July 14 - India's pharmaceutical pricing regulator has cut and capped the prices of more than 100 drugs used to treat diseases ranging from diabetes to HIV to malaria, a move likely to hit the profit margins of drug firms like Sanofi SA, Abbott Laboratories and Ranbaxy Laboratories Ltd.
MUMBAI - The BSE Sensex and Nifty rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained after rival Accenture Plc reported robust quarterly revenue growth.
WASHINGTON/MUMBAI - Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration (FDA) to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.
* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained